GNH USA

Europe — EMA

Ituxredi

GNH USA supplies Ituxredi (Rituximab), a monoclonal antibody for non‑Hodgkin lymphoma, chronic lymphocytic leukemia and rheumatoid arthritis.

Rituximab

Request sourcing

1
Pack/s

What is Rituximab?

Rituximab, the active ingredient in Ituxredi, is a monoclonal antibody presented as a intravenous solution for intravenous use. It treats certain cancers and autoimmune diseases in adult patients, including lymphomas, leukemia and rheumatoid arthritis.

GNH USA supplies Ituxredi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

What is Rituximab used for?

Ituxredi (rituximab) targets B‑cell malignancies and autoimmune disorders by binding CD20 on lymphocytes. Clinical applications include: - Non‑Hodgkin lymphoma: reduces malignant B‑cell proliferation and improves remission rates. - Chronic lymphocytic leukemia: depletes circulating malignant B‑cells, extending survival. - Rheumatoid arthritis: diminishes joint inflammation by eliminating pathogenic B‑cells. - Granulomatosis with polyangiitis: controls vasculitis through B‑cell suppression. - Microscopic polyangiitis: reduces disease activity by targeting CD20‑positive cells.

What are the side effects of Rituximab?

Rituximab may cause a range of adverse reactions during and after infusion.

Common Side Effects: - Infusion‑related reactions: fever, chills, rigors. - Nausea and vomiting. - Fatigue or weakness. - Headache. - Mild hypotension. - Rash or pruritus.

Serious or Rare Side Effects: - Severe infections, including opportunistic pathogens. - Reactivation of hepatitis B virus. - Progressive multifocal leukoencephalopathy (PML). - Anaphylaxis or severe hypersensitivity. - Cardiac arrhythmias. - Cytopenias such as neutropenia or thrombocytopenia.

What precautions apply to Rituximab?

Before initiating Ituxredi, clinicians should assess patient history and monitor for potential complications. - Screen for hepatitis B: test patients for prior infection and monitor viral load. - Monitor for infusion reactions: observe patients during and after administration. - Assess infection risk: avoid use in active severe infections. - Pregnancy considerations: prescribe only when benefits outweigh potential risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

What does Rituximab interact with?

Rituximab can interact with other therapies, requiring careful management.

Major Interactions (Avoid): - Live vaccines: contraindicated during treatment due to immunosuppression. - Cytotoxic chemotherapy: may increase myelosuppression and infection risk. - Other immunosuppressants: heightened susceptibility to infections.

Moderate Interactions (Monitor Closely): - Anticoagulants: potential increase in bleeding tendency. - Azithromycin: may contribute to QT interval prolongation. - Antiviral agents: monitor for altered efficacy.

Frequently asked questions

What conditions is Ituxredi used to treat?+
Ituxredi contains rituximab, which is indicated for several B‑cell related disorders. It is used in the management of non‑Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis. In each case, the drug works by targeting CD20‑positive B cells to reduce disease activity.
How does rituximab work in the body?+
Rituximab is a monoclonal antibody that binds to the CD20 antigen on B‑lymphocytes. This binding activates complement pathways and recruits immune cells, leading to antibody‑dependent cellular cytotoxicity and programmed cell death. The result is selective depletion of CD20‑expressing B cells, which are central to the pathology of the indicated diseases.
What is the usual dose of Ituxredi?+
The dosing regimen for Ituxredi is individualized based on the specific indication, patient characteristics, and treatment protocol. The prescribing physician determines the appropriate dose, infusion rate, and schedule. Patients should follow the dosing instructions provided by their healthcare professional and not adjust the regimen on their own.
Is Ituxredi safe to use during pregnancy or breastfeeding?+
The safety of rituximab in pregnancy and lactation has not been fully established. It is generally recommended to avoid use unless the potential benefits justify the potential risks to the fetus or infant. Women of childbearing potential should discuss contraception and pregnancy plans with their physician before starting therapy.
How do I order Ituxredi from GNH USA?+
To request Ituxredi, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details—including cold‑chain logistics—and necessary import documentation.
How does Ituxredi compare with other treatments for the same conditions?+
Rituximab is a biologic therapy that specifically targets CD20‑positive B cells, offering a mechanism distinct from conventional chemotherapy or small‑molecule immunosuppressants. Compared with some alternatives, it provides targeted B‑cell depletion with a different safety profile, often allowing for combination with other agents. Choice of therapy depends on disease stage, patient tolerance, and physician assessment.
What are the storage requirements for Ituxredi?+
Ituxredi must be stored refrigerated at 2‑8 °C. The product should be kept in its original packaging, protected from light, and must not be frozen or shaken. Maintaining the cold chain during transport and handling is essential to preserve product stability and efficacy.
How is Ituxredi administered to patients?+
Ituxredi is supplied as an intravenous solution and is administered by a qualified healthcare professional through an IV infusion. The infusion rate and duration are determined by the prescribing physician and may be adjusted based on patient tolerance and the specific treatment protocol.
What are the most serious risks associated with Ituxredi?+
Serious risks include severe infections, hepatitis B reactivation, progressive multifocal leukoencephalopathy (PML), anaphylaxis, and cardiac arrhythmias. Patients should be monitored closely for signs of infection, liver dysfunction, neurological changes, and allergic reactions throughout treatment and follow‑up periods.
Who should not receive Ituxredi?+
Ituxredi is contraindicated in patients with known hypersensitivity to rituximab or any component of the formulation. It should also be avoided in individuals with active severe infections, uncontrolled cardiac disease, or those who have received live vaccines within four weeks of treatment. Clinical judgment is required for each patient.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Rituximab
Route
Intravenous Use
Manufacturer
Dr. Reddy's Laboratories (Uk) Ltd
Origin
EU

Related products

A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU